"FDA-Registered" vs. "FDA-Approved": Why This Distinction Is the Key to Spotting an Unproven Stem Cell Clinic

What This Article Covers

A large share of the marketing language used by stem cell clinics rests on a single piece of regulatory sleight-of-hand: the word "registered" standing in for the word "approved." This article explains what each term actually means under U.S. law, why the gap between them is so easy for marketing to exploit, and what a prospective patient can concretely check — from ClinicalTrials.gov status to informed consent documents — before paying for an unproven procedure.

What "FDA-Registered" Actually Means

Under 21 CFR Part 1271, any facility that manufactures human cells, tissues, or cellular and tissue-based products (HCT/Ps) — including many clinics offering "stem cell" injections — must register as an establishment and list its products with the FDA within five days of starting operations, then renew that registration annually. This is an administrative filing, not a scientific review. The FDA's own tissue-establishment registration page states plainly that "acceptance of an establishment registration and HCT/P listing does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA." In other words, a clinic can be fully "FDA-registered" while offering a product the FDA has never evaluated for safety or effectiveness.

What "FDA-Approved" Actually Requires

Approval is a different order of scrutiny entirely. A biologic — which is how most cell-based therapies are classified — can only be marketed after its manufacturer submits a Biologics License Application (BLA) supported by data from adequate and well-controlled clinical trials, typically conducted under an Investigational New Drug (IND) application, demonstrating safety and efficacy for a specific indication. Per the FDA's consumer alert on regenerative medicine products, the only stem cell products currently FDA-approved are certain blood-forming (hematopoietic) stem cell products derived from cord blood, and only for specified blood and immune disorders. No stem cell or exosome product is approved to treat orthopedic conditions, neurological disease, autism, cardiovascular disease, or chronic pain — despite these being among the most commonly marketed uses.

Why the Confusion Is So Profitable

Because "FDA-registered" sounds authoritative to a layperson, clinics can print it on a webpage or brochure and let visitors infer a level of oversight that was never actually performed. This is not a hypothetical concern: the FDA has repeatedly issued warning letters and public safety alerts to businesses marketing unapproved stem cell and exosome products, including a 2019 public safety notification following adverse events tied to unapproved exosome products, in which the agency reminded consumers that "there are currently no FDA-approved exosome products." The gap between registration and approval is precisely the space in which that kind of marketing operates — and it is worth stressing that plenty of legitimately registered establishments operate within the rules; registration alone simply cannot tell a patient which category a given clinic falls into.

The Minimal-Manipulation and Homologous-Use Test

FDA guidance on HCT/Ps (21 CFR 1271.10) sets out when a cell-based product can stay under the lighter "registration-only" pathway versus needing full premarket approval. To qualify, a product must be minimally manipulated (processing doesn't change the tissue's fundamental biological or structural characteristics) and put to homologous use (it performs the same basic function in the recipient that it performed in the donor). Using a patient's own fat-derived cells to treat arthritis or multiple sclerosis, for example, is generally considered non-homologous, since fat tissue's "basic function" isn't cartilage regeneration or remyelination — which is exactly the kind of use that should trigger IND/BLA requirements rather than a simple office procedure.

A Practical Checklist Before Evaluating Any Clinic

• Is the treatment listed on ClinicalTrials.gov, and if so, is it an active, IRB/Ethics-Review-Board-approved trial rather than a "registry" or "study" you pay to join?
• Will the clinic name the Institutional Review Board overseeing the treatment, and can that board be independently verified?
• Does the informed consent document disclose that the treatment is experimental, list specific risks, and confirm you will not be charged simply to participate?
• Does the clinic claim its product treats multiple, unrelated conditions (a common red flag noted by the ISSCR) rather than one narrowly studied indication?
• Is the product homologous in use, or is it being repurposed for a function the source tissue doesn't naturally perform?
• Are claims backed by peer-reviewed, published data — or mainly by testimonials?

Bottom Line

"FDA-registered" is a floor, not a ceiling: it reflects a facility's compliance with basic paperwork requirements, not a judgment about whether its treatments work or are safe. "FDA-approved" reflects an entirely different bar — completed clinical trials reviewed by federal regulators. Most clinics offering unproven stem cell procedures are, in fact, registered; very few are approved for the conditions they advertise. Patients who understand this distinction, and who take the extra step of checking trial registration, IRB oversight, informed consent quality, and whether a product's use is truly homologous, are far better positioned to tell a legitimate research pathway from a marketing pitch.